Facilitating Global Innovation & Partnering


3rd Annual Global Drug Bioavailability Enhancement Summit

Curtis & Coulter

Date/Time: July 11, 2018 - July 12, 2018, 8:00 am - 5:00 pm

Loading Map....

Most drugs on today’s market display poor solubility, but the use of modern solubilization technologies can improve a drug product’s bioavailability and performance. Even the most promising API, monoclonal antibody or therapeutic peptide can only be turned into an effective and marketable drug if formulated in such a way that it is bioavailable. However, finding the ideal solution that gives a particular drug the desired profile is still a major headache for pharmaceutical firms. Additionally, biopharmaceutical firms hoping to develop oral delivery alternatives for biologics will also need to work out how to maximize the bioavailability, safety and effectiveness of their products. Small-and large-molecule therapeutics urgently need to overcome drug formulation and delivery challenges in order to improve bioavailability and therapeutic performance.


The 3rd Annual Global Drug Bioavailability Enhancement Summit will provide a holistic overview to bioavailability enhancements. The summit will cover everything from large molecules to small molecules; oral drugs and parenterals (including nasal, pulmonary, transdermal, microneedles, ocular and more); as well as bridging the gap from early to late stage discovery and development. Throughout the program the summit will discuss real-world stories and case-studies and cover the sessions and topics with best practices and lessons learned in interesting and interactive sessions, panels and roundtables instead of the standard, “mundane” traditional-style presentations.